Citations

Showing 10 of 108162 citations.

Development of quality indicators for the diagnosis and management of achalasia
Kamal, A. N. , Kathpalia, Priya , Otaki, Fouad , Bredenoord, Albert J. , Castell, Donald O., Clarke, John O. , Fass, Ronnie , Gyawali, C. Prakash , Katz, Philip O. , Katzka, David A. , Pandolfino, John E. , Richter, Joel E. , Savarino, Edoardo , Vaezi, Michael F. , Vela, Marcelo F. , Leiman, David A. , Kamal, Afrin N , Fass, Ronnie , Gyawali, C P , Penagini, Roberto , Roman, S , Triadafilopoulos, George , Leiman, David A , Clarke, J , Savarino, Edoardo , Otaki, Fouad , Falk, Gary W. , Kahrilas, Peter J. , Penagini, Roberto , Roman, Sabine , Triadafilopoulos, George

Mayo Clinic

Neurogastroenterology & Motility | March 15, 2021 | Volume: 33 | Issue: 10 | Pages: No page available

10.1111/nmo.14118 | PMID 33720448 Get It

AbstractBackgroundThe management of achalasia has improved due to diagnostic and therapeutic innovations. However, variability in care delivery remains and no established measures defining quality of care for this population exist. We aimed to use formal methodology to establish quality indicators for achalasia patients.MethodsQuality indicator concepts were identified from the literature, consensus guidelines and clinical experts. Using RAND/University of California, Los Angeles (UCLA) Appropriateness Method, experts in achalasia independently ranked proposed concepts in a two‐round modified Delphi process based on 1) importance, 2) scientific acceptability, 3) usability, and 4) feasibility. Highly valid measures required strict agreement (≧ 80% of panelists) in the range of 7–9 for across all four categories.Key ResultsThere were 17 experts who rated 26 proposed quality indicator topics. In round one, 2 (8%) quality measures were rated valid. In round two, 19 measures were modified based on panel suggestions, and experts rated 10 (53%) of these measures as valid, resulting in a total of 12 quality indicators. Two measures pertained to patient education and five to diagnosis, including discussing treatment options with risk and benefits and using the most recent version of the Chicago Classification to define achalasia phenotypes, respectively. Other indicators pertained to treatment options, such as the use of botulinum toxin for those not considered surgical candidates and management of reflux following achalasia treatment.Conclusions & InferencesUsing a robust methodology, achalasia quality indicators were identified, which can form the basis for establishing quality gaps and generating fully specified quality measures.
The Clinical Utility of High-Resolution Vessel Wall Imaging in Screening for Meningovascular Neurosyphilis
Kayyali, Mohammad N , Momii, Austin, Xiao, Jiayu , Fan, Zhaoyang , Dumitrascu, Oana M.

Mayo Clinic

The Neurohospitalist | March 15, 2021 | Volume: 12 | Issue: 1 | Pages: 63-66

10.1177/19418744211000524 | PMID 34950388 Get It

Meningovascular neurosyphilis is a common cause of stroke in young adults, particularly when HIV co-infection is present. Contemporary screening for neurosyphilis relies on invasive testing. High resolution vessel wall imaging (HR-VW) is an emerging non-invasive tool to detect intracranial vessel wall inflammation. We report a case of multifocal acute cerebral infarctions from meningovascular neurosyphillis in which HR-VWI was instrumental in leading to the etiological diagnosis. A 32-year-old man with history of untreated HIV and polysubstance abuse presented with sudden onset vertigo. CT angiogram of the head and neck showed non-dominant left extracranial vertebral artery occlusion in the V1 segment, and multifocal areas of stenoses in V2 through V4 segments. Non-contrast brain MRI demonstrated multiple small acute infarcts in the left cerebellum, left brachium pontis, medulla and occipital lobe. Rapid plasma reagin was reactive. 3D whole-brain HR-VWI revealed concentric vessel wall contrast enhancement in the left V4 segment, suggestive of inflammation. This HR-VWI finding prompted further investigation with cerebrospinal fluid analysis that revealed reactive fluorescent treponemal antibody absorption test. The patient received high-dose intravenous Penicillin G, was restarted on highly active antiretroviral therapy, and remained neurologically stable to-date. With high spatial resolution and signal-to-noise ratio, HR-VWI allows for visualization of vessel wall inflammation in co-morbid HIV and neurosyphilis.
Comparison of In Situ Hybridization, Immunohistochemistry, and Reverse Transcription–Droplet Digital Polymerase Chain Reaction for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Testing in Tissue
Roden, Anja C. , Vrana, Julie A. , Koepplin, Justin W. , Hudson, Angela, Norgan, Andrew P. , Jenkinson, Garrett , Yamaoka, Satoko , Monroe, R. J., Szabolcs, Matthias, Majumdar, Ramanath, Moyer, Ann M. , García, Joaquín J. , Kipp, Benjamin R. , Hudson, Angela E, Norgan, Andrew P , Ebihara, Hideki , Monroe, Robert

Mayo Clinic

Archives of Pathology & Laboratory Medicine | March 15, 2021 | Volume: 145 | Issue: 7 | Pages: 785-796

10.5858/arpa.2021-0008-sa | PMID 33720333 Get It

Context.— Small case series have evaluated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detection in formalin-fixed, paraffin-embedded tissue using reverse transcription–polymerase chain reaction, immunohistochemistry (IHC), and/or RNA in situ hybridization (RNAish). Objective.— To compare droplet digital polymerase chain reaction, IHC, and RNAish to detect SARS-CoV-2 in formalin-fixed, paraffin-embedded tissue in a large series of lung specimens from coronavirus disease 2019 (COVID-19) patients. Design.— Droplet digital polymerase chain reaction and RNAish used commercially available probes; IHC used clone 1A9. Twenty-six autopsies of COVID-19 patients with formalin-fixed, paraffin-embedded tissue blocks of 62 lung specimens, 22 heart specimens, 2 brain specimens, and 1 liver, and 1 umbilical cord were included. Control cases included 9 autopsy lungs from patients with other infections/inflammation and virus-infected tissue or cell lines. Results.— Droplet digital polymerase chain reaction had the highest sensitivity for SARS-CoV-2 (96%) when compared with IHC (31%) and RNAish (36%). All 3 tests had a specificity of 100%. Agreement between droplet digital polymerase chain reaction and IHC or RNAish was fair (κ = 0.23 and κ = 0.35, respectively). Agreement between IHC and in situ hybridization was substantial (κ = 0.75). Interobserver reliability was almost perfect for IHC (κ = 0.91) and fair to moderate for RNAish (κ = 0.38–0.59). Lung tissues from patients who died earlier after onset of symptoms revealed higher copy numbers by droplet digital polymerase chain reaction (P = .03, Pearson correlation = −0.65) and were more likely to be positive by RNAish (P = .02) than lungs from patients who died later. We identified SARS-CoV-2 in hyaline membranes, in pneumocytes, and rarely in respiratory epithelium. Droplet digital polymerase chain reaction showed low copy numbers in 7 autopsy hearts from ProteoGenex Inc. All other extrapulmonary tissues were negative. Conclusions.— Droplet digital polymerase chain reaction was the most sensitive and highly specific test to identify SARS-CoV-2 in lung specimens from COVID-19 patients.
Therapeutic Drug Monitoring of Second- and Third-Generation Antiepileptic Drugs
Krasowski, Matthew D., Long, Thomas A., Snozek, Christine L. H., Dizon, Annabel, Magnani, Barbarajean, Melanson, Stacy E. F., Melanson, Stacy E.F. , Krasowski, Matthew D. , Krasowski, Matthew D , Long, Thomas A., Snozek, Christine L. H., Dizon, Annabel, Magnani, Barbarajean

Mayo Clinic

Archives of Pathology & Laboratory Medicine | March 15, 2021 | Volume: 145 | Issue: 12 | Pages: 1485-1491

10.5858/arpa.2020-0562-cp | PMID 33720327 Get It

Context.— Therapeutic drug monitoring has traditionally been widely used for first-generation antiepileptic drugs (AEDs) such as carbamazepine and phenytoin. The last 2 decades have seen the introduction of second- and third-generation AEDs (eg, lamotrigine, levetiracetam, and topiramate) into clinical practice. Objective.— To use data from the College of American Pathologists Therapeutic Drug Monitoring, Extended Proficiency Testing Survey to determine the performance of assays used for therapeutic drug monitoring of newer AEDs, including comparison of enzyme immunoassay and chromatographic techniques. Design.— Six years of proficiency testing surveys were reviewed (2013–2018). Results.— Steady growth was seen in participant volumes for newer AEDs. The analytical performance of automated enzyme immunoassays for lamotrigine, levetiracetam, and topiramate was similar to that of chromatographic methods, consistent with published literature using patient samples for comparisons. The majority of participating laboratories now use enzyme immunoassays to measure levetiracetam. Conclusions.— Survey results reflect steadily growing interest in therapeutic drug monitoring of newer AEDs. The increasing availability of robust immunoassays for new AEDs should facilitate their clinical utility, especially for clinical laboratories that do not perform chromatographic assays for therapeutic drug monitoring.
Robust, flexible, and scalable tests for Hardy–Weinberg equilibrium across diverse ancestries
Kwong, Alan , Blackwell, Thomas W. , LeFaive, Jonathon , Barnes, Kathleen C. , Boerwinkle, Eric , Cade, Brian E. , Chen, Han , Conomos, Matthew P. , Eng, Celeste , Gao, Yan , Irvin, Marguerite R. , Kelly, Tanika N. , Kim, Wonji , Lubitz, Steven A. , Mathias, Rasika A. , Montasser, May E. , Musani, Solomon K., Palmer, Nicholette D, Qiao, Dandi , Reiner, Alex P. , Roden, Dan M. , Shoemaker, M. Benjamin , Smith, Jennifer A. , Smith, Nicholas L. , Lasky‐Su, Jessica , Tiwari, Hemant K., Weeks, Daniel E. , Group, TOPMed Analysis Working, Scott, Laura J. , Smith, Albert V. , Boehnke, Michael , Kang, Hyun Min , Palmer, Nicholette D. , Smith, Jennifer A , Lubitz, Steven A , Smith, Albert V , Kelly, Tanika N , Weeks, Daniel E , Palmer, Nicholette D , Mathias, Rasika A , Cade, Brian E , Lasky-Su, Jessica , Andrade, Mariza de , Barnard, John , Blangero, John , Burchard, Esteban G. , Chasman, Daniel I. , Cupples, L. Adrienne , Ellinor, Patrick T. , Guo, Xiuqing , Kooperberg, Charles , Mak, Angel C. Y. , Manichaikul, Ani , Montgomery, Courtney G. , Peloso, Gina M. , Roden, Dan M. , Weiss, Scott T. , Group, TOPMed Analysis Working, Abecasis, Gonçalo R.

Mayo Clinic

Genetics | March 15, 2021 | Volume: 218 | Issue: 1 | Pages: No page available

10.1093/genetics/iyab044 | PMID 33720349 Get It

Abstract Traditional Hardy–Weinberg equilibrium (HWE) tests (the χ2 test and the exact test) have long been used as a metric for evaluating genotype quality, as technical artifacts leading to incorrect genotype calls often can be identified as deviations from HWE. However, in data sets composed of individuals from diverse ancestries, HWE can be violated even without genotyping error, complicating the use of HWE testing to assess genotype data quality. In this manuscript, we present the Robust Unified Test for HWE (RUTH) to test for HWE while accounting for population structure and genotype uncertainty, and to evaluate the impact of population heterogeneity and genotype uncertainty on the standard HWE tests and alternative methods using simulated and real sequence data sets. Our results demonstrate that ignoring population structure or genotype uncertainty in HWE tests can inflate false-positive rates by many orders of magnitude. Our evaluations demonstrate different tradeoffs between false positives and statistical power across the methods, with RUTH consistently among the best across all evaluations. RUTH is implemented as a practical and scalable software tool to rapidly perform HWE tests across millions of markers and hundreds of thousands of individuals while supporting standard VCF/BCF formats. RUTH is publicly available at https://www.github.com/statgen/ruth.
Extrapolation of ACOSOG Z0011 trial results—A survey of breast cancer providers
Weiss, Anna , Cooley, Victoria , Al‐Hilli, Zahraa , Poorvu, Nancy , Haffty, Bruce G. , Nelson, Heidi , Blair, Sarah L. , Boughey, Judy, Ballman, Karla V. , Hunt, Kelly K. , Boughey, Judy C.

Mayo Clinic

The Breast Journal | March 15, 2021 | Volume: 27 | Issue: 6 | Pages: 537-542

10.1111/tbj.14226 | PMID 33720478 Get It

Premature or early bilateral oophorectomy: a 2021 update
Rocca, Walter A. , Rocca, Liliana Gazzuola , Mielke, Michelle M. , Stewart, Elizabeth A.

Mayo Clinic

Climacteric | March 15, 2021 | Volume: 24 | Issue: 5 | Pages: 466-473

10.1080/13697137.2021.1893686 | PMID 33719814 Get It

Implications of Atrial Fibrillation on the Mechanisms of Mitral Regurgitation and Response to MitraClip in the COAPT Trial
Gertz, Zachary M. , Herrmann, Howard C. , Lim, D. Scott , Kapadia, Samir , Reed, Grant W. , Puri, Rishi , Krishnaswamy, Amar , Gersh, Bernard J. , Weissman, Neil J., Grayburn, Paul , Redfors, Björn , Zhang, Zixuan , Abraham, William T. , Stone, Gregg W. , Mack, Michael J. , Kapadia, Samir , Herrmann, Howard C , Gersh, Bernard J , Reed, Grant W , Lim, D Scott , Kar, Saibal , Asch, Federico M. , Kosmidou, Ioanna , Lindenfeld, JoAnn

Mayo Clinic

Circulation: Cardiovascular Interventions | March 15, 2021 | Volume: 14 | Issue: 4 | Pages: No page available

10.1161/circinterventions.120.010300 | PMID 33719505 Get It

Background: Atrial fibrillation (AF), mitral regurgitation (MR), and left ventricular (LV) ejection fraction have a complex interplay. We evaluated the role of AF in patients with heart failure and moderate-to-severe or severe secondary MR enrolled in the randomized COAPT trial (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation) and its impact on mechanisms and outcomes with the MitraClip. Methods: Patients in the COAPT trial were stratified by the presence (n=327) or absence (n=287) of a history of AF and by assignment to treatment group. Clinical, echocardiographic, and outcome measures were assessed. The primary outcome was the composite rate of death or heart failure hospitalization at 24 months. Results: Patients with history of AF were older and more often male. They had a higher LV ejection fraction, larger left atrial volumes and mitral valve orifice areas, smaller LV volumes, and similar MR severity. Patients with AF compared with those without a history of AF had a higher unadjusted (hazard ratio [HR], 1.32 [95% CI, 1.06–1.64], P =0.01) and adjusted (HR, 1.30 [1.03–1.64], P =0.03) 2-year rate of the primary outcome. Treatment with the MitraClip compared with guideline-directed medical therapy alone reduced death or heart failure hospitalization in both those with (HR, 0.61 [0.46–0.82]) and without (HR, 0.46 [0.33–0.66]) a history of AF ( P int =0.18). Treatment with the MitraClip was associated with a lower risk of stroke in patients with a history of AF (HR, 0.18 [0.04–0.86]) but not in those without a history of AF (HR, 1.64 [0.58–4.62]; P int =0.02). Conclusions: In the COAPT trial, patients with a history of AF had larger left atrial and mitral valve orifice areas with higher LV ejection fraction and smaller LV volumes, suggesting an atrial mechanism contribution to functional MR. Despite the worse prognosis of heart failure patients with a history of AF, MR reduction with the MitraClip still afforded substantial clinical benefits. Treatment with MitraClip was associated with a lower risk of stroke in patients with a history of AF. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01626079.
Placental Immune Responses to Viruses: Molecular and Histo-Pathologic Perspectives
Narang, Kavita , Cheek, Elizabeth, Enninga, Elizabeth Ann L. , Theiler, Regan N. , Cheek, Elizabeth H, Enninga, Elizabeth Ann L , Theiler, Regan , Cheek, Elizabeth H.

Mayo Clinic

International Journal of Molecular Sciences | March 14, 2021 | Volume: 22 | Issue: 6 | Pages: 2921

10.3390/ijms22062921 | PMID 33805739 Get It

As most recently demonstrated by the SARS-CoV-2 pandemic, congenital and perinatal infections are of significant concern to the pregnant population as compared to the general population. These outcomes can range from no apparent impact all the way to spontaneous abortion or fetal infection with long term developmental consequences. While some pathogens have developed mechanisms to cross the placenta and directly infect the fetus, other pathogens lead to an upregulation in maternal or placental inflammation that can indirectly cause harm. The placenta is a temporary, yet critical organ that serves multiple important functions during gestation including facilitation of fetal nutrition, oxygenation, and prevention of fetal infection in utero. Here, we review trophoblast cell immunology and the molecular mechanisms utilized to protect the fetus from infection. Lastly, we discuss consequences in the placenta when these protections fail and the histopathologic result following infection.
Microvascular Transposition Without Teflon: A Single Institution's 17-Year Experience Treating Trigeminal Neuralgia
Pines, Andrew R. , Butterfield, Richard , Turcotte, Evelyn L. , García, José Omar de Armas , Lucia, Noel De, Algier, Emily J, Zimmerman, Richard S. , Garcia, Jose O, De Lucia, Noel, Patel, Naresh P.

Mayo Clinic

Operative Neurosurgery | March 14, 2021 | Volume: 20 | Issue: 4 | Pages: 397-405

10.1093/ons/opaa413 | PMID 33432975 Get It

Abstract BACKGROUND Trigeminal neuralgia (TN) refractory to medical management is often treated with microvascular decompression (MVD) involving the intracranial placement of Teflon. The placement of Teflon is an effective treatment, but does apply distributed pressure to the nerve and has been associated with pain recurrence. OBJECTIVE To report the rate of postoperative pain recurrence in TN patients who underwent MVD surgery using a transposition technique with fibrin glue without Teflon. METHODS Patients were eligible for our study if they were diagnosed with TN, did not have multiple sclerosis, and had an offending vessel that was identified and transposed with fibrin glue at our institution. All eligible patients were given a follow-up survey. We used a Kaplan-Meier (KM) model to estimate overall pain recurrence. RESULTS A total of 102 patients met inclusion criteria, of which 85 (83%) responded to our survey. Overall, 76 (89.4%) participants responded as having no pain recurrence. Approximately 1-yr pain-free KM estimates were 94.1% (n = 83), 5-yr pain-free KM estimates were 94.1% (n = 53), and 10-yr pain-free KM estimates were 83.0% (n = 23). CONCLUSION Treatment for TN with an MVD transposition technique using fibrin glue may avoid some cases of pain recurrence. The percentage of patients in our cohort who remained pain free at a maximum of 17 yr follow-up is on the high end of pain-free rates reported by MVD studies using Teflon. These results indicate that a transposition technique that emphasizes removing any compression near the trigeminal nerve root provides long-term pain-free rates for patients with TN.